



# Thinking Beyond COVID: Pulmonary Cases from the Wards

Zachary Hartsell, DHA, PA-C

# Objectives

---

- Define and classify acute respiratory failure as: hypoxemic, hypercapnic, or mixed.
- Describe the pathophysiology and manifestations of acute respiratory failure.
- Review oxygen supplementation techniques.
- Discuss when the use of NIPPV is most appropriate.
- Diagnose acute respiratory distress syndrome correctly and review the best treatment options for this condition.

\*Assume all cases are COVID negative

# Mrs. Kent

---

ABG

- 42 yo female, with a past medical history of breast cancer, presents to the hospital with a 5-hour history of **chest pain and shortness of breath.**
  - PMH: Breast CA s/p R mastectomy (in remission), hypothyroidism
  - Medications: Levothyroxine
  - SH: Smokes ½ pack of cigarettes per day, occasional EtOH use. She just came back from a vacation to Hawaii with her family.
  - Vitals: **HR**: 116, **RR**: 30, **BP**: 110/69, **Temp**: 37.5°C,
  - **O2 sat**: 85% on RA
  - PE: She is is moderate respiratory distress and using some of her accessory muscles. Lungs sound clear.



# Mrs. Kent

---

- **ABG:**

- pH: 7.34

- PaCO<sub>2</sub>: 31

- PaO<sub>2</sub>: 48

- Bicarb: 25




# Which type of respiratory failure does this patient have?

---

- A. Hypoxic
- B. Hypercapnic
- C. Mixed
- D. "I have no idea...but I'm worried"

# Hypoxemic Respiratory Failure

- **PaO<sub>2</sub> < 80mmHg**
- Abnormal PaO<sub>2</sub>/FiO<sub>2</sub> ratio
- Common causes of hypoxemia:
  - **Ventilation/perfusion mismatch**
  - Impaired gas diffusion
  - Alveolar hypoventilation
  - High altitude



# Oxygen Delivery Devices

---

- Nasal cannula
- Simple face mask
- Non-rebreather mask
- Face Tent
- High-flow nasal cannula

# Nasal Cannula

---

- Typically provides **1-6** L/min continuous O<sub>2</sub> flow
- Approximate FiO<sub>2</sub>:
  - 1L = 0.24 (24%)
  - **6L = 0.44** (~44%)
- Comfortable, readily available, and improves oxygenation





# Face Mask

---



- Delivers humidified oxygen
- Provides a higher FiO<sub>2</sub> than a nasal cannula
  - **6 – 10** L/min of oxygen
  - **0.4 - 0.6** FiO<sub>2</sub>
- Good for “mouth breathers”

# Non-rebreather Mask

---

- Delivers non-humidified oxygen
  - **10 – 15 L/min O<sub>2</sub>**
  - **FiO<sub>2</sub> range = 0.6 – 0.9**
- Reservoir bag provides 100% FiO<sub>2</sub>, and consists of one-way valves which minimize room air dilution
- Carries a risk of suffocation if the gas flow is interrupted (the bag should never fully deflate)



# Face Tent

---



- Covers the nose and mouth, and does not create a seal around the nose
- Delivers cool, aerosolized oxygen
  - Can provide **0.4 – 0.5 FiO<sub>2</sub>**
- Helpful with facial burns, trauma or surgery...or with claustrophobia.

# High-flow Nasal Cannula

---




- Heated & humidified oxygen
- Rates up to **60** L/min & **1.0** FiO<sub>2</sub> (100%)
- Improves work of breathing
- Enhances gas exchange
- More comfortable than BiPAP
- Greatly decreases intubation rates in hypoxemic respiratory failure



# Mrs. Kent

---

- Diagnosed with an **acute pulmonary embolism**
- Initially placed on nasal cannula, but with ongoing hypoxia was transitioned to high-flow nasal cannula
- Heparin drip initiated



# Mr. Jones

---

- 75yo male, with a past medical history of **COPD**, type 2 **diabetes**, and HLD presents to the ER with a 3-day history of “**worsening shortness of breath**”.
  - Medications: Metformin, Albuterol PRN, Advair Diskus
  - SH: 50 pack year history of smoking cigarettes and cigars. Daily EtOH use. He is retired and lives at home with his wife.
  - Vitals: **HR**: 105, **RR**: 34, **BP**: 119/75  
**Temp**: 37.8°C **O2 sat**: 87% on RA
  - He is in moderate distress, using accessory muscles, and wheezing.



# Mr. Jones

---

- ABG
  - pH = 7.40
  - pCO<sub>2</sub> = 48
  - pO<sub>2</sub> = 53
  - Bicarb = 30

~~12 12~~  
~~12 28~~ 325

135	102	12	135
3.7	29	0.8	



# Mr. Jones

---

- In the ER, he received:
  - Albuterol/ipratropium nebulizer
  - IV Solu-medrol
  - IV Levofloxacin
- Despite this, he continues to be hypoxic. His O2 sat is 83% on 4L NC.



# What would be the next step in your treatment plan?

---

- A. ↑ O<sub>2</sub> to 6l via nasal cannula
- B. Start high-flow nasal cannula
- C. Start BiPAP
- D. Intubate

# Respiratory Support for COPD Exacerbations

Consider in very severe underlying COPD (FEV1<30%) if hypoxemia seems to be the main concern

**High-flow nasal cannula**

*Shown to reduce intubation, mortality*



**Supplemental oxygen**

**NIPPV**

**Mechanical ventilation**

If  $\geq 1$  of following:

- PaCO<sub>2</sub>  $\geq 45$  and pH  $\leq 7.35$
- Severe dyspnea, increased WOB, accessory muscle use
- Persistent hypoxemia despite  $\uparrow$  O<sub>2</sub>

*Shorter LOS, improved survival, decreased hypercarbia/improved ventilation*

# Mr. Jones

---

- You decide to place Mr. Jones on HFNC and he starts to improve
- However, a few hours later you get a call that he is more lethargic...

## ABG

pH = 7.21

pCO<sub>2</sub> = 67

pO<sub>2</sub> = 72

# What should we do now?

---

- A. Go back to nasal cannula
- B. Continue high-flow nasal cannula
- C. Start BiPAP
- D. Intubate

# NIPPV

---

- Advantages of using noninvasive positive pressure ventilation (NIPPV):
  - Avoid complications of intubation
  - Preserves airway reflexes
  - Improves patient comfort
  - Decreases need for sedation
  - Shortens hospital/ICU stay
  - Improves survival

# BiLevel Positive Airway Pressure (BiPAP)

---

INDICATIONS	CONTRAINDICATIONS
<ul style="list-style-type: none"><li>• <b>Hypercapnia and acidosis</b></li><li>• Cardiogenic pulmonary edema</li><li>• COPD exacerbation</li><li>• Weaning and post- extubation failure</li><li>• Post surgical period</li><li>• Obesity hypoventilation syndrome</li><li>• Neuromuscular disorders</li><li>• Poor alveolar oxygen exchange</li></ul>	<ul style="list-style-type: none"><li>• Impaired neurological state</li><li>• Respiratory arrest</li><li>• Shock or severe cardiovascular instability</li><li>• Excessive airway secretions</li><li>• Vomiting</li><li>• Facial lesions/deformity preventing good mask fit</li><li>• Significant agitation</li><li>• Acute severe non respiratory organ failure</li></ul>

# Ms. Brown

---

- 23yo female with a past medical history of depression and anxiety is brought to the ED via EMS. She was found in her home, obtunded, by her boyfriend. She had several pill bottles next to her.
  - PMH: depression, anxiety
  - Medications: Amitriptyline, Xanax PRN
  - SH: Daily alcohol use, lifelong non-smoker.
  - Vitals: **HR**: 119, **RR**: 7, **BP**: 89/50, **Temp**: 38.2°C, **O2 sat**: 94% RA
  - PE: Pupils dilated, dry mouth, GCS 5



# Ms. Brown

---

- **ABG:**

– pH: 7.15

– PaCO<sub>2</sub>: 71

– PaO<sub>2</sub>: 70

– Bicarb: 24



**Respiratory  
Acidosis!**



# Hypercapnic Respiratory Failure

---

- **Excess CO<sub>2</sub> production or decreased effective alveolar ventilation**
  - Alveolar minute ventilation (VA) is determined by the tidal volume (VT) and respiratory rate (f). VD is dead space.
    - $VA = (VT - VD)f$

# Hypercapnic Respiratory Failure

---

## Causes:

- **Acute airway obstruction**: foreign body, tumor, laryngospasm/bronchospasm
- **Lung disease**: Severe pneumonia/PE/COPD exacerbation, pulmonary edema, pulmonary fibrosis
- **CNS depression**: drugs (narcotics), CNS event, trauma, central sleep apnea
- **Neuromuscular disorder**: Guillain-Barré, myasthenia gravis, brain stem or spinal cord injury
- Obesity hypoventilation
- Impaired lung motion
- Inappropriate mechanical ventilation settings

# Would BiPAP be appropriate for Ms. Brown?


---

- A. Yes
- B. No
- C. "I have no idea...but I'm worried"

# Indications for Intubation

- Airway protection
- Relief of obstruction
- Respiratory failure
  - Refractory hypoxemia and/or hypercapnia
- Respiratory arrest
- Shock
- Intracranial hypertension
- Bronchopulmonary toilet
- Requires sedation/analgesia

## The decision to intubate



# Mrs. Sands

---

- A 28yo female presented as a transfer from an outside hospital with **shortness of breath, cough and occasional hemoptysis**
- She was recently diagnosed with **SLE** the previous year but was not on any immunosuppression at this time



# Mrs. Sands

---

- She was hemodynamically stable and admitted to the hospital
- Only 2 episodes of hemoptysis in the past 24 hours
  
- She was given 1g Solu-Medrol
- The next day, she was taken for an elective bronchoscopy to workup the hemoptysis

# Mrs. Sands

---

- During the bronchoscopy, she developed massive hemoptysis 2/2 **diffuse alveolar hemorrhage**
- She became hypoxic and hypercapnic, as well as hemodynamically unstable

~~10.6      7.6  
                 277  
22.6~~

~~135 | 9 | 12  
-----  
3.7 | 29 | 0.8~~ 135

# Hemoptysis

## Causes of Hemoptysis

### Cause:

#### Cryptogenic

#### Pulmonary

- Airway infections (bronchitis, PNA, lung abscess)
- Bronchial carcinoma/Mets
- Bronchiectasis/CF
- Pulmonary edema/mitral stenosis
- TB
- Invasive aspergillosis
- Benign bronchial tumors
- Vasculitis

#### Cardiovascular

- Pulmonary artery embolism
- Vascular malformations
- Idiopathic pulmonary hemosiderosis
- Septic embolism/right heart endocarditis
- Pulmonary HTN

#### Other

- Iatrogenic: lung biopsy, R heart catheterization, medications, anticoagulations
- Trauma/lung contusion
- Foreign body
- Coagulopathy
- Thrombocytopenia



# Hemoptysis

---

- **Massive hemoptysis** = 100 – 600 ml of blood loss in 24h
  - Conservatively treated massive hemoptysis has a **mortality of 50-100%**
  - Death is usually secondary to asphyxia, as opposed to blood loss/hemorrhagic shock

# Initial Management of Hemoptysis

---

- Ensure adequate vascular access (e.g. 2 large bore IV)
- Monitor vital signs closely
- Give oxygen
- Place the patient with the **bleeding side down**
- Secure the airway (intubation)
  - Use a large diameter ET tube, or consider unilateral intubation if indicated
- Sedation/anxiolysis or paralytics if necessary
- Reverse any coagulopathy that may be present.
  - Transfuse blood products if indicated

# Treatment of Hemoptysis

---

- Mild - moderate hemoptysis can be treated conservatively
- **Bronchoscopy**
  - Typically, first line for diagnostic (localize site of bleeding) and therapeutic intervention
  - Can help remove the blood to help with gas exchange
  - Stop bleeding with laser or cryotherapy, electrocautery, or argon plasma coagulation
- **Bronchial artery embolization**
- Surgery

# Mrs. Sands

---

- Upon close workup, her SLE labs were negative, but she was p-ANCA and MPO positive
  - Rheumatology made the diagnosis of **DAH 2/2 microscopic polyangiitis**
- She received a prolonged high-dose steroid taper, plasma exchange, and Rituximab
  - She improved clinically, and was able to be discharged

# Mrs. Wilson

---

- 63 yo female, with a history of HTN, HLD, rheumatoid arthritis who was brought in by her husband for acute SOB.
- Mrs. Wilson has had low grade fevers and a dry cough for the last 2-3 weeks. Her grandkids visited her last week and she thought she picked up a cold from them. She is COVID negative.
- When she woke up this morning, she felt significantly worse and says she couldn't catch her breath.
- Nursing reports to you that she was hypoxic in triage on nasal canula.



“Mr. Wilson is **hypoxic**, please evaluate ASAP”

# Mrs. Wilson

---


- PMH: HTN, HLD, rheumatoid arthritis
- Medications: HCTZ, atorvastatin, prednisone 20 mg, methotrexate 10 mg weekly, folic acid
- SH: Former ½ pack smoker x 30 years, occasional EtOH use. No recent travel.
- Flu and pneumonia vaccines UTD
- Vitals: **HR**: 101, **RR**: 27, **BP**: 110/79, **Temp**: 38.9 C  
**O2 sat**: 87% on 4L
- PE: She is in moderate respiratory distress and using accessory muscles. Course breath sounds B/L.

# Mrs. Wilson

---

$$\begin{array}{r} 13.2 \\ \times 277 \\ \hline 10.6 \\ \times 38 \\ \hline \end{array}$$

$$\begin{array}{r|l} 128 & 9 & 18 \\ \hline 3.7 & 90 & 0.8 \end{array} \left. \begin{array}{l} \\ \\ \end{array} \right\} 135$$



# What is the most appropriate next test?

---

- A. D-dimer
- B. LDH
- C. Arterial blood gas (ABG)
- D. CT- Scan of the Chest



# Diagnosis of *Pneumocystis jiroveci* Pneumonia

---

- AKA *Pneumocystis carinii* pneumonia (PCP)
  - The *PCP* abbreviation is still used in addition to *PJP*
- Spike in incidence in late 1980's and 1990's as a result of the HIV epidemic
  - Incidence declined as a result of better HIV treatments
- Rise in last 10 years due to immunosuppressant use in cancer, transplant and inflammatory diseases
- 1-2% of patients with RA on combined therapy
- 5-15% of patients undergoing solid organ transplantation or bone marrow transplantation

# Risk Factors for *Pneumocystis jirovecii* Pneumonia

- HIV infection whose CD4 + cells fall below 200/ $\mu$ L and who are not receiving PJP prophylaxis
- Primary immune deficiencies, including some forms of hypogammaglobinemia and severe combined immunodeficiency (SCID)
- Long-term immunosuppressive regimens
- Active hematologic and nonhematologic malignancies, including solid tumors and lymphomas
- Severe malnutrition

# Diagnosis of Pneumocystis jirovecii Pneumonia

---

- Transmission is airborne.
  - Typically, asymptomatic immunocompetent individuals who are colonized.
- Classically presents as fulminant respiratory failure with associated fevers and dry cough
  - Can present with lesser but persistent symptoms
    - Indolent dyspnea
    - Chronic cough
    - Extrapulmonary symptoms
- Labs can show normal WBC and elevated LDH.
  - Hyponatremia is possible
- CXR can vary from “normal” CXR to interstitial infiltrates to ARDS
- ABG can show high Aa gradient, respiratory alkalosis
- Definitive diagnosis based on histopathology, BAL has 90% diagnostic yield

# Treatment of *Pneumocystis jirovecii* Pneumonia

- Begin treatment based on high clinical suspicion and clinical findings, do not wait for definitive diagnosis
  - Mortality rate in non-HIV infected patient range between 30-50%
- While a fungus, traditional antifungals are not effective
- 1<sup>st</sup> line treatment is TMP- SMX
- Second line therapies include pentamidine, dapsone or atovaquone
- Adjunct corticosteroids are **NOT** recommended in non-HIV patients

# Mrs. Wilson

---

- You start Mrs. Wilson on IV TMP-SMX treatment for PJP.
- You place her on 4L/min of O<sub>2</sub> via nasal cannula, and her saturations improve.

# Key Points

---

- When a patient is in respiratory distress, first determine if it is hypoxic, hypercapnic, or mixed respiratory failure.
- Use the most appropriate form of supplemental O<sub>2</sub>.
- Consider high-flow nasal cannula, even in COPD exacerbations.
- Do not delay intubation if it is necessary.
- With hemoptysis, turn patient to bleeding side down, and secure an airway first.
- Treat PJP pneumonia early

# References

---

- Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. *CID* **2007**:44 (Suppl 2)
- Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia: **2016** Clinical Practice Guidelines by the IDSA and ATS. *CID* 2016:1-43.
- Killu K, Sarani B, eds. *Fundamental Critical Care Support, 6th Edition*. Mount Prospect, IL: Society of Critical Care Medicine; 2017.
  - Mechanical Ventilation. *FCCS 5<sup>th</sup> Ed. SCCM*, 2012. pp 5-7
  - Diagnosis and Management of Acute Respiratory Failure. *FCCS 6<sup>th</sup> Ed. SCCM*, 2017. pp. 45-60
- Brown 3rd CA, Walls RM. The decision to intubate. In: *The Walls Manual of Emergency Airway Management, 5th ed*, Lippincott Williams & Wilkins, Philadelphia 2018. p.3
- Global Initiative for Chronic Obstructive Lung Disease, the 2018 Report.
- Scalera NM and File TM. How long should we treat community acquired pneumonia? *Curr opin Infect Dis.* 2007; 20:177-181
- The ARDS Definition Task Force. Acute Respiratory Distress Syndrome: The Berlin Definition. *JAMA* 2012; May 21, 2012
- Ittrich H, Bockhorn M, Klose H, Simon M: The diagnosis and treatment of hemoptysis. *Dtsch Arztebl Int* 2017; 114; 371-81. DOI: 10.3238/artztebl.2017.0371
- Gilroy, *Pneumocystis jiroveci Pneumonia (PJP) Overview of Pneumocystis jiroveci Pneumonia*, Medscape, 2019